Tag Archives: clinical commissioning groups
September 2014 Br J Cardiol 2014;21(suppl 1):S1–S11
European experiences reviewed
David Hargroves
Background The novel oral anticoagulant (NOAC) agents (dabigatran, rivaroxaban, apixaban) have had a disproportionally poor uptake since their respective launches and National Institute for Health and Care Excellence (NICE) Technology Appraisal in the UK between 2012 and 2013 for their use in stroke prevention in patients with non-valvular atrial fibrillation (NVAF), when compared with our European counterparts; particularly Germany, Holland and France. In the original NICE economic analyses for the NOACs there was a calculated uptake of approximately 20% in the first year,1 the figure currently runs at <8% with many area’s significantly
February 2014 Br J Cardiol 2014;21:14 Online First
Building an effective business case to support heart failure services
Andrew L Clark
Audit The stage was set by Professor Theresa McDonagh (King’s College, London) who showed how the National Heart Failure Audit can be used as a tool to support business case development. Professor McDonagh highlighted that “data is power”. She discussed how the audit allows service providers to demonstrate to commissioners the potential gains that can be made by providing adequate services for patients admitted to hospital. In particular, the audit highlights how the best outcomes are achieved for patients who are admitted to hospital under the care of cardiologists and are subsequently followed up by a cardiologist. The next step, once
March 2013 Br J Cardiol 2013;20(suppl 2):S1–S11 doi:10.5837/bjc.2013.s02
Acute heart failure – a call to action
Professor Martin Cowie, Professor Derek Bell, Mrs Jane Butler, Professor Henry Dargie, Professor Alasdair Gray, Professor Theresa McDonagh, Dr Hugh McIntyre, Professor Iain Squire, Dr Jacqueline Taylor, Ms Helen Williams
(more…)
For healthcare professionals only
